DTP Vaccine


DTP vaccine is a white homogeneous colloidal suspension, in glass vial, containing purified diphtheria toxoid, purified tetanus toxoid, and inactivated B. pertussis orga nisms. The toxoids are adsorbed onto aluminum phosphate.


Each dose (0.5 mL) contains :
Active Ingredients :

• Purified diphtheria toxoid    20  Lf
• Purified tetanus toxoid          7.0 Lf
• Inactivated B. pertussis         12  OU
Excipients :

• Aluminum phosphate 1.5 mg
• Thimerosal                    0.05 mg

Active immunization against diphtheria, tetanus, and pertussis infections for children, simultaneously.

Mechanism of action
Stimulate the body to produce antibodies against diphtheria, tetanus, and pertussis.

Side effects
Mild local or systemic reactions are common. Some temporary swelling, tenderness and redness at the site of injection together with fever occur in a large proportion of cases.

Occasionally severe reactions of high fever, irritability and high pitch crying develop within 24 hours of administration.

Hypotonic-hyporesponsive episodes have been reported. Febrile convulsions have been reported at a rate of one per 12,500 doses administered.

Administration of acetaminophen at the time of 4-8 hours after immunization decreases the subsequent incidence of febrile reactions.

The national childhood encephalopathy study in the United Kingdom showed a small increased risk of acute encephalopathy (primarily seizures) following DTP immunization. However subsequent detailed reviews of all available studies by a number of groups, including the United States Institute of Medicine, the Advisory Committee on Immunization Practices, and the paediatric associations of Australia, Canada, the United Kingdom and the United States, concluded that the data did not demonstrate a causal relationship between DTwP and chronic nervous system dysfunction in children. Thus there is no scientific evidence that hypotonic-hyporesponsive episode and febrile convulsions have any permanent consequences for the children. In which, after DTP administration occur hypersensitive reaction, subsequent immunization dose is replaced to DT or DTaP.


  • DTP vaccine should not be given to individuals with anaphylactic reaction to a previous dose or to any constituent of the vaccine.
  • Hypersensitive to one component of vaccine
  • Children with cough, common cold, fever, and nerve abnormality, prone to seizure, asthma and dermatitis.

Immune deficiency
Individuals infected with human immunodeficiency virus (HIV), both asymptomatic and symptomatic, should be immunized with DTP vaccine according to standard schedules.

Drug interaction
Not reported

Warning & precaution

  • Should not be given to children above 5 years
  • See information on vaccine administration (page 87)


  • DTP Vaccine must be stored at temperatures between +2°C to +8°C.
  • Expiry date 2 years.

The Use of Multi-dose Vial Vaccine
Multi-dose vials of DTP from which one or more doses of vaccine have been removed during an immunization session may be used in subsequent immunization session for up to a maximum of 4 weeks, provided that all of required conditions are met.


Box : 10 vials @ 5 mL (10 doses)